Navin Fluorine International (532504) investor relations material

Executive summary

• Q1 FY26 revenue rose 39% year-over-year to INR 725 crores, with operating EBITDA up 106% to INR 207 crores and net profit up 129% to INR 117 crores.

• All business divisions—HPP, Specialty Chemicals, and CDMO—reported robust growth, supported by a strong order book and successful project ramp-ups.

• A successful INR 750 crore QIP was completed, receiving strong investor response and strengthening the balance sheet.

• Unaudited standalone and consolidated financial results for Q1 FY26 were approved and reviewed by the Board and auditors.

• The group operates solely in the chemical business segment, including several domestic and international subsidiaries and a joint venture.

Financial highlights

• Consolidated revenue for Q1 FY26 was INR 725–739 crores, up 39% year-over-year and 3% sequentially.

• Operating EBITDA reached INR 207 crores, up 106% year-over-year, with a margin of 28.5%, up 935 bps.

• Profit after tax was INR 117 crores, up 129% from Q1 FY25.

• Operating PBT for the quarter was INR 141 crores, up 143% year-over-year.

• Net debt to equity stood at 0.34x.

Outlook and guidance

• Management remains optimistic about sustained momentum, with a solid order book and ongoing expansion projects.

• Margin guidance remains above 25%, with current EBITDA margin at 28.5%; management prefers to observe a few more quarters before updating guidance.

• CapEx framework expanded to INR 700–1000 crores over FY26–27, with disciplined project selection.

• AHF capex of INR 450 crores at Dahej expected to commission by end Q2 FY26; supplies for three new specialty molecules to start in Q2 FY26.

• CDMO business expects major commercial orders from US and EU in FY26.